Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 5 Sarcoma 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Fallopian Tube Neoplasms 2 Vulvar Neoplasms 1 Recurrence 1 Neuroendocrine Tumors 1 Neoplasms 1 Liver Neoplasms 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Gallbladder Neoplasms 1 Disease 1 Colorectal Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Neuroendocrine 1 Breast Neoplasms 1 Bile Duct Neoplasms 1 Advanced Adult Hepatocellular Carcinoma 1

Interventions

Temozolomide 264 Radiotherapy 119 Bevacizumab 105 Magnetic Resonance Spectroscopy 59 Radiation 47 pembrolizumab 30 Irinotecan 28 Surgical Procedures, Operative 23 Lomustine 21 Specimen Handling 19 Nivolumab 19 Radiosurgery 18 Carmustine 18 Aminolevulinic Acid 16 Erlotinib Hydrochloride 15 Drug Therapy 15 Blood Specimen Collection 14 Radiotherapy, Intensity-Modulated 13 O(6)-benzylguanine 13 Chemotherapy, Adjuvant 13 Carboplatin 13 Filgrastim 11 Cyclophosphamide 11 sargramostim 10 poly ICLC 10 atezolizumab 10 Thalidomide 10 Etoposide 10 Ipilimumab 9 Everolimus 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Glioblastoma × tivozanib × Clear all

NCT01846871 2019-01-08

Tivozanib for Recurrent Glioblastoma

Massachusetts General Hospital

Phase 2 Completed

10 enrolled 13 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡